Abbott (NYSE: ABT) today announced that the U.S. Food and Drug Administration (FDA) has approved an investigational device exemption (IDE) for its Coronary Intravascular Lithotripsy (IVL) System to ...
Abbott's Coronary IVL System wins FDA IDE nod, offering a potential new treatment for arterial calcium blockages.
Abbott received FDA investigational device exemption (IDE) approval for its coronary intravascular lithotripsy (IVL) system.
• Ultrasound guidance may lead to a higher first-attempt success rate and improved time to successful common femoral artery (CFA) access, while reducing the venipuncture rate (unintentionally ...
Abbott has announced that the U.S. Food and Drug Administration (FDA) has approved an investigational device exemption (IDE) ...
Johnson & Johnson and Boston Scientific have also recently made moves to sell their own coronary intravascular lithotripsy ...
Bob Lowth Ford General Manager Todd Moudry had long been in good health, so when he was diagnosed with an ascending aortic aneurysm in 2018, he could hardly believe it was true. The discovery traces ...
In atherosclerosis, the vascular smooth muscle cell (VSMC) contributes to vessel wall inflammation and lipoprotein retention, as well as to the formation of the fibrous cap that provides stability ...
Human extracellular matrices can be edited in their composition using the CRISPR/Cas9 system, leading to materials exhibiting tailored regenerative capacities.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback